Are Mukka Proteins Ltd latest results good or bad?

1 hour ago
share
Share Via
Mukka Proteins Ltd's latest results show significant revenue volatility, with a 41.76% quarterly decline in net sales, although net profit increased by 51.73% year-on-year. Overall, the company faces operational challenges and concerns about sustainability despite some improvements in profitability metrics.
Mukka Proteins Ltd's latest financial results for Q4 FY26 present a complex picture of the company's performance. The net sales for the quarter were reported at ₹380.61 crores, reflecting a significant quarter-on-quarter decline of 41.76% from the previous quarter's exceptional sales of ₹653.50 crores. Year-on-year, net sales saw a marginal contraction of 0.25%, indicating stagnation in core operations amidst notable volatility in revenue generation over recent quarters.
Despite the revenue challenges, Mukka Proteins reported a consolidated net profit of ₹20.62 crores for Q4 FY26, which represents a year-on-year increase of 51.73%. However, this figure also reflects a quarter-on-quarter decline of 13.18%. The operating profit margin, excluding other income, improved to 9.21% from 7.84% in the same quarter last year, suggesting better cost management. Nevertheless, the company's reliance on non-operating income remains a concern, as it constituted over half of the profit before tax. The overall financial trajectory reveals operational inconsistencies, with the company experiencing substantial fluctuations in sales figures across recent quarters. The full-year FY25 results showed stronger performance, with net sales reaching ₹1,449.53 crores and a consolidated profit of ₹51.77 crores. However, the recent quarterly performance raises questions about the sustainability of this growth. Mukka Proteins' evaluation has seen an adjustment, reflecting the underlying operational challenges and market conditions. The company faces significant issues, including negative operating cash flow of ₹111 crores for FY25, high leverage indicated by a debt-to-EBITDA ratio of 4.93 times, and a declining trend in institutional investor participation. The stock's performance has also lagged behind the broader FMCG sector, highlighting investor skepticism regarding the company's ability to deliver consistent value. In summary, Mukka Proteins Ltd's latest results indicate a company grappling with revenue volatility and operational challenges, despite some improvements in profitability metrics. The financial data suggests a need for the company to address these structural issues to regain investor confidence and ensure sustainable growth moving forward.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
When is the next results date for Mukka Proteins Ltd?
May 13 2026 11:17 PM IST
share
Share Via
Mukka Proteins Ltd is Rated Sell
May 06 2026 10:10 AM IST
share
Share Via
Mukka Proteins Ltd is Rated Sell
Apr 25 2026 10:10 AM IST
share
Share Via
Mukka Proteins Ltd is Rated Sell
Apr 14 2026 10:10 AM IST
share
Share Via